McNeil, JJ and Woods, RL and Nelson, MR and Murray, AM and Reid, CM and Kirpach, B and Storey, E and Shah, RC and Wolfe, RS and Tonkin, AM and Newman, AB and Williamson, JD and Lockery, JE and Margolis, KL and Ernst, ME and Abhayaratna, WP and Stocks, N and Fitzgerald, SM and Trevaks, RE and Orchard, SG and Beilin, LJ and Donnan, GA and Gibbs, P and Johnston, CI and Grimm, RH, on behalf of the ASPREE Investigator Group, Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study, Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 72, (11) pp. 1586-1593. ISSN 1079-5006 (2017) [Refereed Article]
© The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved.
Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).
Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.
Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
|Item Type:||Refereed Article|
|Keywords:||Clinical trial, Dementia, Disability, Primary prevention|
|Research Division:||Medical and Health Sciences|
|Research Group:||Cardiorespiratory Medicine and Haematology|
|Research Field:||Cardiology (incl. Cardiovascular Diseases)|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Cardiovascular System and Diseases|
|Author:||Nelson, MR (Professor Mark Nelson)|
|Web of Science® Times Cited:||1|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page